Global Seed Treatment (Fungicide, Insecticide, Bio-Control,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Seed Treatment (Fungicide, Insecticide, Bio-Control, and Others) Market - Trends, Forecasts and Technical Insights up to 2019

Dublin, July 23, 2014 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/tp..._treatment ) has announced the addition of the "Seed Treatment Market by Type, by Application and by Crop - Global Trends, Forecasts and Technical Insights up to 2019" report to their offering.

This report provides a comprehensive outlook on the global seed treatment market with respect to various regions, product types, and applications.

In terms of value, the market is estimated to be worth $2,798.0 million in 2014 and is projected to reach $4,635.4 million by 2019, growing at a CAGR of 10.6% from 2014 to 2019. Growth in terms of value is estimated to be higher than that in terms of volume, owing to the increasing cost of agrochemicals. Development and registration of a pesticide active ingredient is one of the biggest components of cost for seed treatment manufacturers.

North America and Latin America were the leading consumers of seed treatments, collectively accounting for over 75.2% of the market until 2013. Constant regulatory push towards restricting the use of agrochemicals and increasing consumer awareness regarding the consequences of agrochemicals residues in food have resulted in a significant increase in demand for seed treatments in other regions as well.

Asia-Pacific, which has witnessed a steady demand for these seed treatments in the recent years, is now one of the growing markets for seed treatment. Increasing modernization of agriculture in India and China is projected to drive the Asia-Pacific market in the near future.

Among all seed treatment applications, seed treatment insecticides (chemical) form the largest segment and are estimated to account for over 50.0%share of the global seed treatment market in 2013. Seed treatment fungicides (chemical) are estimated to form the second-largest segment of the global seed treatment market with 34.2% share in 2013.

In terms of competition, the market is dominated by innovators, which are essentially companies with patented products in the market. Key innovators include Bayer CropScience AG (Germany), Syngenta AG (Switzerland), BASF SE (Germany) and Nufarm Company (Australia). Also, there are companies that focus on bio-control seed treatment products, which are products with natural active ingredient. Key participants in the bio-control segment include Plant Health Care Inc. (U.S.) and Becker Underwood (U.S.).


Key Topics Covered:

1 Introduction

2 Executive Summary

3 Premium Insights

4 Market Overview

5 Seed Treatment Market, By Type

6 Seed Treatment Market, By Target Protection

7 Seed Treatment Market, By Target Crop (Page No. - 205)

8 Seed Treatment Technologies: the Future Prospective

9 Seed Treatment Market, By Geography

10 Competitive Landscape

11 Company Profiles


Companies Mentioned:

  • Advanced Biological Marketing
  • BASF SE
  • Bayer Cropscience Ag
  • Chemtura Corporation
  • E.I. Du Pont De Nemours and Company
  • Monsanto
  • Morflora
  • Novozymes A/S
  • Nufarm Limited
  • Sumitomo Chemical Company Limited


For more information visit http://www.researchandmarkets.com/research/tp..._treatment

Research and Markets Laura Wood, Senior Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Agriculture, Food

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading